Ligand Pharmaceuticals (LGND) Capital Expenditures (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Capital Expenditures of $228000.0 for Q1 2026, up 6.05% sequentially from $215000.0 in Q4 2025, and up 6.54% YoY from $214000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Capital Expenditures (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Capital Expenditures for 17 years, with the latest figure at $228000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 6.54% year-over-year to $228000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229000.0 (down 88.13% YoY) and the FY2025 annual result came in at $215000.0, down 88.19% from the prior year.
- Capital Expenditures improved to $228000.0 in Q1 2026 per LGND's latest filing, from $215000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $14.3 million in Q4 2022 and troughed at -$3.1 million in Q4 2023.
- A 5-year average of $1.2 million and a median of $215000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures tumbled 177.34% in 2022, then surged 1578.16% in 2023.
- Over 5 years, Capital Expenditures stood at $14.3 million in 2022, then plunged by 121.71% to -$3.1 million in 2023, then jumped by 122.94% to $712000.0 in 2024, then plunged by 69.8% to $215000.0 in 2025, then increased by 6.05% to $228000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $228000.0, $215000.0, and -$9000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 26,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26,000.00 |
| Jun 30, 2026 | 26,000.00 |
| Mar 31, 2026 | 228,000.00 |
| Mar 31, 2026 | 228,000.00 |
| Dec 31, 2025 | 215,000.00 |
| Dec 31, 2025 | 215,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | -205,000.00 |
| Jun 30, 2025 | -205,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Mar 31, 2025 | 214,000.00 |
| Dec 31, 2024 | 712,000.00 |
| Dec 31, 2024 | 712,000.00 |
| Sep 30, 2024 | 596,000.00 |
| Sep 30, 2024 | 596,000.00 |
| Jun 30, 2024 | 408,000.00 |
| Jun 30, 2024 | 408,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Mar 31, 2024 | 105,000.00 |